Callan Family Office’s West Pharmaceutical WST Stock Holding History

Callan Family Office’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48M	Sell	4,116 -1,251	-23%	-$382K	0.03%	482
2026 Q1	$1.35M	Sell	5,367 -440	-8%	-$109K	0.03%	477
2025 Q4	$1.6M	Buy	5,807 +3,519	+154%	+$963K	0.03%	409
2025 Q3	$600K	Sell	2,288 -1,181	-34%	-$287K	0.02%	487
2025 Q2	$759K	Buy	3,469 +1,496	+76%	+$320K	0.02%	461
2025 Q1	$442K	Buy	1,973 +314	+19%	+$86.5K	0.03%	352
2024 Q4	$543K	Buy	+1,659	New	+$522K	0.03%	351

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Callan Family Office's WST Position: Q2 2026 in Review

Callan Family Office reduced its West Pharmaceutical (WST) stake by 23% in Q2 2026, selling an estimated $382K and leaving 4,116 shares worth $1.48M. The position accounts for 0.03% of the portfolio, ranked #482.

Callan Family Office first reported a position in WST in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.6M in Q4 2025. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

Callan Family Office held 4,116 shares of West Pharmaceutical worth $1.48M as of Q2 2026.
Callan Family Office sold 1,251 West Pharmaceutical shares in Q2 2026, an estimated $382K.
West Pharmaceutical made up 0.03% of Callan Family Office's portfolio in Q2 2026, its #482 holding.
Callan Family Office first reported a position in West Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
Callan Family Office's West Pharmaceutical position peaked at $1.6M in Q4 2025.
830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.